Acceleron Pharma Inc (NASDAQ:XLRN) Shorts Decreased By 0.07% As Of Jun 29, 2018

June 29, 2018 - By Ronnie Lemelle

Acceleron Pharma Inc. (NASDAQ:XLRN) Corporate Logo

Big Money Sentiment increased to 1.27 in Q1 2018. It has change of 0.18, from 2017Q4’s 1.09. The ratio improved due to Acceleron Pharma Inc. positioning: 13 sold and 39 reduced. 24 funds took positions and 42 increased positions. Investors holded 38.14 million in 2017Q4 but now own 38.30 million shares or 0.44% more.
Fmr Limited Liability Company accumulated 5.17 million shs. Schwab Charles Investment Management Incorporated, California-based fund reported 192,271 shs. Mackay Shields Lc holds 16,083 shs or 0% of its capital. First Manhattan Communications holds 0.03% in Acceleron Pharma Inc. (NASDAQ:XLRN) or 155,600 shs. New Jersey-based Lord Abbett Com Limited Liability Corp has invested 0.01% in Acceleron Pharma Inc. (NASDAQ:XLRN). Artal Grp Inc holds 850,000 shs or 0.42% of its capital. Manufacturers Life Insur The owns 28,217 shs. Farallon Capital Management Limited Liability Company owns 0.38% invested in Acceleron Pharma Inc. (NASDAQ:XLRN) for 1.40 million shs. Swiss Bankshares has invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Tekla Capital Mgmt Ltd Co owns 273,098 shs or 0.42% of their US capital. Eagle Asset Mgmt, Florida-based fund reported 1.23 million shs. 10,500 were accumulated by Bailard. Vanguard Group invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Tiaa Cref Invest Llc stated it has 86,811 shs or 0% of all its holdings. Barclays Public Limited Co has 28,105 shs.

Acceleron Pharma Inc. registered $4.08 million net activity with 0 insider buys and 12 insider sales since January 2, 2018. Quisel John D sold $183,806 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) or 4,333 shs on Tuesday, January 2. MCLAUGHLIN KEVIN F sold $814,848 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) on Tuesday, January 2. On Tuesday, January 2 the insider Kumar Ravindra sold $182,363. 4,633 shs were sold by Sherman Matthew L, worth $197,868. On Tuesday, March 6 POPS RICHARD F also sold $1.55 million worth of Acceleron Pharma Inc. (NASDAQ:XLRN).

Acceleron Pharma Inc (NASDAQ:XLRN) showed a decrease of 0.07% in shorted shares. FINRA published shorted shares of XLRN’s total 2.73 million shares. That’s 0.07% down from 2.73M shares. Acceleron Pharma Inc (NASDAQ:XLRN) has 280,800 shares average volume. It’ll cost 10 days for XLRN to restore its former position. Acceleron Pharma Inc float short is 7.08%.

XLRN touched $48.536 during the last trading session after $14.556 change.Acceleron Pharma Inc. has 3.09 million shares volume, 843.92% up from normal. XLRN is uptrending and has moved 37.77% since June 29, 2017. XLRN outperformed by 25.20% the S&P 500.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases.The firm is valued at $2.22 billion. The Company’s therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases.Last it reported negative earnings. The company??s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Coverage

A total of 5 analysts rate Acceleron Pharma (NASDAQ:XLRN) as follows: 4 “Buy”, 1 “Hold” and 0 “Sell”. Тherefore 80% are bullish. (NASDAQ:XLRN) has 7 ratings reports on Jun 29, 2018 according to StockzIntelligence. On Monday, January 8 the rating was initiated by H.C. Wainwright with “Buy”. On Monday, February 26 JP Morgan upgraded the shares of XLRN in report to “Overweight” rating. On Wednesday, February 28 the rating was maintained by Barclays Capital with “Overweight”. On Thursday, March 1 the firm earned “Buy” rating by Citigroup. On Wednesday, February 28 the stock has “Buy” rating by H.C. Wainwright. On Wednesday, March 28 H.C. Wainwright initiated the shares of XLRN in report with “Buy” rating. On Tuesday, May 22 the rating was initiated by Oppenheimer with “Hold”.

For more Acceleron Pharma Inc. (NASDAQ:XLRN) news posted briefly go to: Globenewswire.com, Streetinsider.com, Benzinga.com, Seekingalpha.com or Fool.com. The titles are as follows: “Market Trends Toward New Normal in RCI Hospitality, Phillips 66 Partners LP, Acceleron Pharma, Destination …” posted on June 22, 2018, “Pre-Open Movers 06/29: (GEMP) (DERM) (NKE) Higher; (PFIE) (STZ) (SNX) Lower (more…)” on June 29, 2018, “10 Biggest Price Target Changes For Friday” with a publish date: June 29, 2018, “Acceleron: Luspatercept New Data Is A Buy Signal” and the last “Big News Is Fast Approaching for Celgene” with publication date: June 08, 2018.

Acceleron Pharma Inc. (NASDAQ:XLRN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.